Breast cancer · 10 regimens
Cost vs Efficacy · 5 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Goserelin, Letrozole, Ribociclib Variant #01 | ER | R 23 809 | 28d | ~22.8 mo | ~58.7 mo | ~25 | ~R 595 219 PFS proxy · indirect | 3 |
Anastrozole, Goserelin, Ribociclib Variant #01 | ER | R 23 597 | 28d | ~22.8 mo | ~58.7 mo | ~25 | ~R 589 925 PFS proxy · indirect | 3 |
Goserelin monotherapy Variant #04 | ER | R 10 511 | 84d | — | — | — | — | — |
Tamoxifen and OFS Variant not yet assigned - class-based regimen | ER | R 6 366 | 28d | — | — | — | — | 3 |
Goserelin and Letrozole Variant #01 | ER | R 2 999 | 28d | ~13.0 mo | ~48.0 mo | ~15 | ~R 44 981 PFS proxy · indirect | 2 |
Anastrozole and Goserelin Variant #01 | ER | R 2 787 | 28d | ~13.0 mo | ~48.0 mo | ~15 | ~R 41 804 PFS proxy · indirect | 2 |
Goserelin and Tamoxifen Variant #01 | ER | R 2 764 | 28d | ~13.0 mo | ~48.0 mo | ~15 | ~R 41 467 PFS proxy · indirect | 2 |
Leuprolide monotherapy Variant #01 | ER | R 2 266 | 90d | — | — | — | — | 2 |
Exemestane and OFS Variant #01 | ER | R 1 859 | 28d | — | — | — | — | — |
Tamoxifen monotherapy Variant #06 | ER | R 410 | 28d | — | — | — | — | 3 |
10 of 10 regimens shown